
Opinion|Videos|April 24, 2024
Future Management and Unmet Needs in Myelofibrosis
Author(s)Prithviraj Bose, MD
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.
Advertisement
Case: Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
- A 68-year-old woman presented to her physician with symptoms of mild fatigue.
- Spleen was palpable 6-7 cm below the left costal margin.
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
- NGS Testing: JAK2 V617F mutation
- Karyotype: 46XX
- BM biopsy: megakaryocyte proliferation and atypia with evidence of reticulin fibrosis
- Blood smear: leukoerythroblastosis
- Diagnosis: Primary myelofibrosis
- Risk:
- DIPSS: Intermediate-2
- Mipss70: Intermediate risk
- Lab Values
- RBC 3.40 x 1012/L
- Hgb 9.7 g/dL
- HCT 32.3%
- MCV 94 fL
- WBC 23.0 x 109/L
- PLT 450 x 109/L
- PB Blasts <1%
Initial Treatments:
- Initiated on ruxolitinib.
- The patient was not interested in transplant.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
T-DXd Improves PFS vs Standard of Care in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Piktor in Endometrial Cancer
4
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
5




































